Kairos Pharma, Ltd. (KAPA) Price & Analysis

Compare

135 Followers

KAPA Stock Chart & Stats

$0.64

-$0.43(-28.67%)

At close: Jan 08 4:00 PM EST

$0.64

-$0.43(-28.67%)

Day’s Range― - ―

52-Week Range$0.40 - $2.11

Previous CloseN/A

Volume680.77K

Average Volume (3M)1.08M

Market Cap

$13.14M

Enterprise Value$7.49M

Total Cash (Recent Filing)$5.58M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.97

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding20,821,354

10 Day Avg. Volume532,234

30 Day Avg. Volume1,076,746

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)3.61

Price to Sales (P/S)0.00

P/FCF Ratio-4.36

Enterprise Value/Market Cap0.57

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-46.83

Enterprise Value/Ebitda-1.57

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)-0.33

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy SignalInterim trial results report extended progression-free survival with multiple patients remaining on therapy, suggesting a potentially durable benefit versus anti-androgen treatment alone.

Mechanism-driven Re-sensitizationTargeting CD105 may re-sensitize tumors to anti-androgen drugs and other targeted agents in resistant disease, potentially expanding treatment options and commercial opportunity.

Safety ProfileReported tolerability with no dose-limiting toxicities indicates a favorable safety profile that could support combination use with standard therapies.

Bears Say

Increased VolatilityRecent trading activity signals heightened volatility that can amplify short-term swings in valuation and deter risk-averse investors.

Interim Data UncertaintyDependence on early, small-cohort interim data creates uncertainty until larger randomized results confirm benefit, exposing the stock to downside if confirmatory trials do not replicate initial signals.

Share Price CorrectionA pronounced share price decline following a prior rally points to profit-taking that can depress the stock independent of fundamental developments.

Kairos Pharma, Ltd. News

Kairos Pharma to acquire CL-273 from Celyn Therapeutics

Kairos Pharma (KAPA) announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, a...

9d ago

KAPA

Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn

Kairos Pharma (KAPA) announced the signing of a term sheet for a strategic asset acquisition with Celyn Therapeutics....

13d ago

KAPA

Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy

Kairos Pharma, Ltd. ( ($KAPA) ) has shared an announcement. On March 2, 2026, Kairos Pharma, Ltd. entered...

9d ago

KAPA

Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal

Kairos Pharma, Ltd. ( ($KAPA) ) has shared an update. On February 26, 2026, Kairos Pharma, Ltd. announced...

13d ago

KAPA

Kairos Pharma files $75M mixed securities shelf

06:02 EST Kairos Pharma (KAPA) files $75M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

KAPA

Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating

Maxim Group analyst Jason McCarthy maintained a Buy rating on Kairos Pharma, Ltd. yesterday and set a price...

4M ago

KAPA

Kairos Pharma Approves RSUs and Cash Bonuses

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On October 8, 2025, Kairos Pharma, Ltd.‘s Compensation...

5M ago

KAPA

Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating

Maxim Group analyst Jason McCarthy has maintained their bullish stance on KAPA stock, giving a Buy rating on...

5M ago

KAPA

Kairos Pharma to Present at ESMO Congress 2025

Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On October 7, 2025, Kairos Pharma announced its...

5M ago

KAPA

Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma

Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

6M ago

KAPA

Kairos Pharma Reports Positive Phase 2 Trial Results

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an update. On September 18, 2025, Kairos Pharma announced positive...

6M ago

KAPA

Kairos Pharma announces interim efficacy analysis of ENV105

Kairos Pharma (KAPA) announced efficacy data from its ongoing Phase 2 clinical trial of ENV105 in patients with...

6M ago

KAPA

Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Kairos Pharma, Ltd., retaining the price target...

6M ago

KAPA

Kairos Pharma to Host KOL Event on Phase 2 Trial

Kairos Pharma, Ltd. ( ($KAPA) ) has shared an announcement. On September 11, 2025, Kairos Pharma announced it...

6M ago

KAPA

KAPA FAQ

What was Kairos Pharma, Ltd.’s price range in the past 12 months?

Kairos Pharma, Ltd. lowest stock price was $0.40 and its highest was $2.11 in the past 12 months.

What is Kairos Pharma, Ltd.’s market cap?

Kairos Pharma, Ltd.’s market cap is $13.14M.

When is Kairos Pharma, Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kairos Pharma, Ltd.’s earnings last quarter?

Currently, no data Available

Is Kairos Pharma, Ltd. overvalued?

According to Wall Street analysts Kairos Pharma, Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kairos Pharma, Ltd. pay dividends?

Kairos Pharma, Ltd. does not currently pay dividends.

What is Kairos Pharma, Ltd.’s EPS estimate?

Kairos Pharma, Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kairos Pharma, Ltd. have?

Kairos Pharma, Ltd. has 20,821,354 shares outstanding.

What happened to Kairos Pharma, Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kairos Pharma, Ltd.?

Currently, no hedge funds are holding shares in KAPA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kairos Pharma, Ltd.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.